Endo International PLC (NASDAQ:ENDP) was down 2.5% during mid-day trading on Monday after Citigroup lowered their price target on the stock from $40.00 to $25.00. Citigroup currently has a buy rating on the stock. Endo International PLC traded as low as $20.20 and last traded at $20.33, with a volume of 1,914,046 shares traded. The stock had previously closed at $20.85.

ENDP has been the subject of several other research reports. Vetr raised shares of Endo International PLC from a “hold” rating to a “buy” rating and set a $21.95 price objective for the company in a research report on Thursday, August 25th. Leerink Swann reaffirmed a “market perform” rating and set a $23.00 price target on shares of Endo International PLC in a report on Wednesday, June 29th. Morgan Stanley set a $16.00 price target on shares of Endo International PLC and gave the company a “hold” rating in a report on Thursday, September 8th. JMP Securities reaffirmed a “buy” rating on shares of Endo International PLC in a report on Wednesday, June 29th. Finally, Mizuho raised shares of Endo International PLC from an “underperform” rating to a “neutral” rating and raised their price target for the company from $13.00 to $16.00 in a report on Monday, June 13th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eleven have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $39.32.

A number of hedge funds have recently modified their holdings of the stock. Meeder Asset Management Inc. bought a new position in Endo International PLC during the first quarter valued at approximately $139,000. Canada Pension Plan Investment Board boosted its position in Endo International PLC by 33.0% in the first quarter. Canada Pension Plan Investment Board now owns 9,019 shares of the company’s stock valued at $254,000 after buying an additional 2,237 shares during the last quarter. Massmutual Trust Co. FSB ADV boosted its position in Endo International PLC by 7.0% in the first quarter. Massmutual Trust Co. FSB ADV now owns 11,377 shares of the company’s stock valued at $320,000 after buying an additional 745 shares during the last quarter. LS Investment Advisors LLC boosted its position in Endo International PLC by 152.3% in the second quarter. LS Investment Advisors LLC now owns 13,661 shares of the company’s stock valued at $213,000 after buying an additional 8,247 shares during the last quarter. Finally, Icon Advisers Inc. Co. bought a new position in Endo International PLC during the second quarter valued at approximately $218,000. Hedge funds and other institutional investors own 96.66% of the company’s stock.

The company’s 50-day moving average is $20.88 and its 200-day moving average is $22.19. The company’s market cap is $4.47 billion.

Endo International PLC (NASDAQ:ENDP) last released its earnings results on Monday, August 8th. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.12. Endo International PLC had a negative net margin of 25.90% and a positive return on equity of 15.54%. The company had revenue of $921 million for the quarter, compared to the consensus estimate of $873.50 million. During the same period in the prior year, the company posted $1.08 EPS. The company’s revenue was up 25.3% compared to the same quarter last year. Equities analysts forecast that Endo International PLC will post $4.56 earnings per share for the current year.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

5 Day Chart for NASDAQ:ENDP

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.